{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T07:40:22Z","timestamp":1732520422823,"version":"3.28.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,24]]},"DOI":"10.7759\/cureus.74372","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:58:40Z","timestamp":1732517920000},"source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Analysis of Rituximab Therapy for Myasthenia Gravis: A Case Series"],"prefix":"10.7759","author":[{"given":"Abeer  S","family":"Albalawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamer S","family":"Albalawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc AM","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021, 14:7-16. 10.25122\/jml-2020-0145","journal-title":"J Med Life"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent A","year":"2018","unstructured":"Vincent A, Huda S, Cao M, et al.. Serological and experimental studies in different forms of myasthenia gravis. Ann NY Acad Sci. 2018, 1413:143-53. 10.1111\/nyas.13592","journal-title":"Ann NY Acad Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis K","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020, 11:212. 10.3389\/fimmu.2020.00212","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.01.007","article-title":"Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models","volume":"270","author":"Plomp JJ","year":"2015","unstructured":"Plomp JJ, Morsch M, Phillips WD, Verschuuren JJ. Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models. Exp Neurol. 2015, 270:41-54. 10.1016\/j.expneurol.2015.01.007","journal-title":"Exp Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-64142-7.00055-2","article-title":"Clinical neurophysiology of neuromuscular junction disease","volume":"161","author":"Juel VC","year":"2019","unstructured":"Juel VC. Clinical neurophysiology of neuromuscular junction disease. Handb Clin Neurol. 2019, 161:291-303. 10.1016\/B978-0-444-64142-7.00055-2","journal-title":"Handb Clin Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis K","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020, 11:596981. 10.3389\/fneur.2020.596981","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz PM","year":"2015","unstructured":"Rodr\u00edguez Cruz PM, Al-Hajjar M, Huda S, et al.. Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol. 2015, 72:642-9. 10.1001\/jamaneurol.2015.0203","journal-title":"JAMA Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda S","year":"2017","unstructured":"Huda S, Waters P, Woodhall M, et al.. IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurol Neuroimmunol Neuroinflamm. 2017, 4:e357. 10.1212\/NXI.0000000000000357","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211065406","article-title":"Advances and challenges in the treatment of myasthenia gravis","volume":"14","author":"Schneider-Gold C","year":"2021","unstructured":"Schneider-Gold C, Gilhus NE. Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord. 2021, 14:17562864211065406. 10.1177\/17562864211065406","journal-title":"Ther Adv Neurol Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher G","year":"2018","unstructured":"Beecher G, Anderson D, Siddiqi ZA. Rituximab in refractory myasthenia gravis: extended prospective study results. Muscle Nerve. 2018, 58:452-5. 10.1002\/mus.26156","journal-title":"Muscle Nerve"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz MD","year":"2006","unstructured":"Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006, 6:859-66. 10.1111\/j.1600-6143.2006.01288.x","journal-title":"Am J Transplant"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1072861","article-title":"Reduced quality of life in myasthenia gravis patients: a study on 185 patients from China","volume":"13","author":"Wu X","year":"2022","unstructured":"Wu X, Li RY, Ye XB, Wang N. Reduced quality of life in myasthenia gravis patients: a study on 185 patients from China. Front Neurol. 2022, 13:1072861. 10.3389\/fneur.2022.1072861","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2311","article-title":"Rituximab in newly diagnosed generalized myasthenia gravis: a new treatment paradigm?","volume":"79","author":"Chuquilin M","year":"2022","unstructured":"Chuquilin M, Barohn R. Rituximab in newly diagnosed generalized myasthenia gravis: a new treatment paradigm?. JAMA Neurol. 2022, 79:1100-2. 10.1001\/jamaneurol.2022.2311","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan R","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017, 56:185-96. 10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan HM","year":"2009","unstructured":"G\u00fcrcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009, 9:10-25. 10.1016\/j.intimp.2008.10.004","journal-title":"Int Immunopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/aian.aian_945_22","article-title":"Clinical profile and quality of life in myasthenia gravis using MGQOL15 R(Hindi): an Indian perspective","volume":"26","author":"Majigoudra G","year":"2023","unstructured":"Majigoudra G, Duggal AK, Chowdhury D, Koul A, Todi VK, Roshan S. Clinical profile and quality of life in myasthenia gravis using MGQOL15 R(Hindi): an Indian perspective. Ann Indian Acad Neurol. 2023, 26:441-6. 10.4103\/aian.aian_945_22","journal-title":"Ann Indian Acad Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21609","article-title":"Construct and concurrent validation of the MG-QOL15 in the practice setting","volume":"41","author":"Burns TM","year":"2010","unstructured":"Burns TM, Grouse CK, Conaway MR, Sanders DB. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010, 41:219-26. 10.1002\/mus.21609","journal-title":"Muscle Nerve"},{"key":"ref18","unstructured":"Clinical Commissioning Policy Statement. Rituximab bio-similar for the treatment of myasthenia gravis (adults). (2021). Accessed: 2024: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/04\/Rituximab-biosimilar-for-the-treatment-of-myasthenia-gravis-adu...."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.83000","article-title":"Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study","volume":"17","author":"Karadurmus N","year":"2021","unstructured":"Karadurmus N, Paydas S, Esin E, et al.. Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study. Arch Med Sci. 2021, 17:920-7. 10.5114\/aoms.2019.83000","journal-title":"Arch Med Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis C","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol Clin. 2018, 36:311-37. 10.1016\/j.ncl.2018.01.011","journal-title":"Neurol Clin"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2021.02.042","article-title":"SY4.3. Therapeutic considerations in myasthenia gravis","volume":"132","author":"Imai T","year":"2021","unstructured":"Imai T. SY4.3. Therapeutic considerations in myasthenia gravis. Clin Neurophysiol. 2021, 132:45. 10.1016\/j.clinph.2021.02.042","journal-title":"Clin Neurophysiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders DB","year":"2010","unstructured":"Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010, 43:428-35. 10.3109\/08916930903518107","journal-title":"Autoimmunity"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard JF Jr.","year":"2017","unstructured":"Howard JF Jr., Utsugisawa K, Benatar M, et al.. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017, 16:976-86. 10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF Jr.","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T, et al.. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021, 20:526-36. 10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak RJ","year":"2011","unstructured":"Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011, 4:259-66. 10.1177\/1756285611411503","journal-title":"Ther Adv Neurol Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner S","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020, 77:974-81. 10.1001\/jamaneurol.2020.0851","journal-title":"JAMA Neurol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak RJ","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, et al.. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2022, 98:e376-89. 10.1212\/WNL.0000000000013121","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of Rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl F","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, et al.. Efficacy and safety of Rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022, 79:1105-12. 10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1278250","article-title":"Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells","volume":"14","author":"Li S","year":"2023","unstructured":"Li S, Zhang Z, Liu Z. Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells. Front Neurol. 2023, 14:1278250. 10.3389\/fneur.2023.1278250","journal-title":"Front Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJ. Myasthenia gravis. Nat Rev Dis Primers. 2019, 5:30. 10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36. 10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio R","year":"2015","unstructured":"Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015, 262:1115-9. 10.1007\/s00415-014-7532-3","journal-title":"J Neurol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.002","article-title":"Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis","volume":"29","author":"Roda RH","year":"2019","unstructured":"Roda RH, Doherty L, Corse AM. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis. Neuromuscul Disord. 2019, 29:554-61. 10.1016\/j.nmd.2019.06.002","journal-title":"Neuromuscul Disord"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and safety of Rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis","volume":"12","author":"Zhao C","year":"2021","unstructured":"Zhao C, Pu M, Chen D, Shi J, Li Z, Guo J, Zhang G. Effectiveness and safety of Rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis. Front Neurol. 2021, 12:736190. 10.3389\/fneur.2021.736190","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/296543-retrospective-analysis-of-rituximab-therapy-for-myasthenia-gravis-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:58:43Z","timestamp":1732517923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/296543-retrospective-analysis-of-rituximab-therapy-for-myasthenia-gravis-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,24]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.74372","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,24]]}}}